GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aspen Pharmacare Holdings Ltd (JSE:APN) » Definitions » Debt-to-EBITDA

Aspen Pharmacare Holdings (JSE:APN) Debt-to-EBITDA : 4.51 (As of Jun. 2024)


View and export this data going back to 1990. Start your Free Trial

What is Aspen Pharmacare Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aspen Pharmacare Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was R11,314 Mil. Aspen Pharmacare Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was R25,142 Mil. Aspen Pharmacare Holdings's annualized EBITDA for the quarter that ended in Jun. 2024 was R8,086 Mil. Aspen Pharmacare Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 4.51.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Aspen Pharmacare Holdings's Debt-to-EBITDA or its related term are showing as below:

JSE:APN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.1   Med: 4.38   Max: 8.2
Current: 4.59

During the past 13 years, the highest Debt-to-EBITDA Ratio of Aspen Pharmacare Holdings was 8.20. The lowest was 2.10. And the median was 4.38.

JSE:APN's Debt-to-EBITDA is ranked worse than
79.12% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs JSE:APN: 4.59

Aspen Pharmacare Holdings Debt-to-EBITDA Historical Data

The historical data trend for Aspen Pharmacare Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspen Pharmacare Holdings Debt-to-EBITDA Chart

Aspen Pharmacare Holdings Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.68 2.81 2.10 3.03 3.68

Aspen Pharmacare Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.61 3.61 3.52 4.63 4.51

Competitive Comparison of Aspen Pharmacare Holdings's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspen Pharmacare Holdings's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aspen Pharmacare Holdings's Debt-to-EBITDA falls into.



Aspen Pharmacare Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aspen Pharmacare Holdings's Debt-to-EBITDA for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(11314 + 25142) / 9914
=3.68

Aspen Pharmacare Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(11314 + 25142) / 8086
=4.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.


Aspen Pharmacare Holdings  (JSE:APN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Aspen Pharmacare Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aspen Pharmacare Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspen Pharmacare Holdings Business Description

Traded in Other Exchanges
Address
Douglas Saunders Drive, Aspen Place, 9 Rydall Vale Park, La Lucia Ridge, Durban, NL, ZAF
Aspen Pharmacare Holdings Ltd is a specialty pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both API and finished dose form. The company focuses on a broad range of post-patent, branded medicines and domestic brands spanning many therapeutic areas. The company has four business segments such as Active Pharmaceutical Ingredients (API) - this segment includes the API Chemicals business and non-heparin biochemical API business, Heparin - this segment includes the full value chain contribution from all heparin containing products including API and Finished Dose. Form (FDF) sales Key products include the Fraxiparine and MonoEmbolex heparin containing FDF products and FDF Steriles segment.

Aspen Pharmacare Holdings Headlines

No Headlines